Form 8-K - Current report:
SEC Accession No. 0000950170-24-078774
Filing Date
2024-06-28
Accepted
2024-06-28 07:33:02
Documents
11
Period of Report
2024-06-28
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K lxeo-20240628.htm   iXBRL 8-K 44188
  Complete submission text file 0000950170-24-078774.txt   161495

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lxeo-20240628.xsd EX-101.SCH 25988
14 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20240628_htm.xml XML 4931
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41855 | Film No.: 241081373
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)